A New Era of Precision Medicine in Gynecologic Cancers

A New Era of Precision Medicine in Gynecologic Cancers

Tuesday, June 22, 2021
Webinar -- 6:30 PM ET


Welcome, Introduction, Polling, and Presurvey Questions

Advances in Current Management of Endometrial Cancers – Dr. Duska

  • Molecular classification
  • Assays and recommendations for dMMR/MSI-H testing
  • Advances in the treatment landscape
    • New clinical data
    • New approvals
  • Management of immune-related AEs 
  • Novel therapies in development
  • Patient case discussion

Advances in Frontline and Recurrent Ovarian Cancers – Dr. Coleman

  • Testing for BRCA1/2 and HRD status
  • PARPi in frontline and recurrent ovarian cancer
  • Novel therapies in development
  • Patient case discussion

Advances in Current Management of Cervical Cancers – Dr. Randall

  • Cervix cancer overview
    • HPV Infection and tumorigenesis
    • HPV vaccination and preventative measures
  • Current treatments algorithms for advanced/metastatic cervix cancer
  • Novel therapies in development
    • Immunotherapy
    • Antibody–drug conjugates
    • PARP inhibitors
  • Case discussion

Audience Q&A Session


Program Director
Linda Duska, MD, MPH

Lawrence W. Penniston MD Family Professor in Women’s Oncology Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert L. Coleman, MD, FACOG, FACS

Gynecologic Oncologist & Chief Scientific Officer
US Oncology, US Oncology Research
The Woodlands, Texas

Leslie M. Randall, MD

Diane Harris Wright Professor and Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Massey Cancer Center
Virginia Commonwealth University
Richmond, Virginia

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in gynecologic malignancies.

Target Audience
This educational program is intended for medical oncologists, gynecologic oncologists, and other healthcare providers who treat patients with cervical, endometrial, and ovarian cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the underlying molecular biology of gynecologic cancers and potential targets for therapy
  • Evaluate current and emerging practice-changing clinical data on checkpoint inhibitors and PARP inhibition as single-agent or combination therapies in cervical, endometrial, and ovarian cancer
  • Plan treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination strategies
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Describe the role of immune checkpoint inhibitor-based therapy in endometrial cancer classified as microsatellite stable


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.